Hematologic Malignancies Program ABSTRACT The goal of the Hematologic Malignancies (HM) Program is to improve outcomes and expand opportunities for patients with leukemia, Hodgkin and non-Hodgkin lymphoma, and multiple myeloma by integrating basic, translational, and clinical research through close collaborations among investigators in the Program. Research collaborations are facilitated through disease- and modality-specific research teams that meet regularly, including leukemia, lymphoma, multiple myeloma, transplant, immunotherapy, and gene therapy. Each of these teams works in an integrated manner and includes multi-disciplinary collaborators from the HM Program as well as from other Cancer Center programs and cores. The Themes of our program are the following: Theme 1: Identify key biological pathways and targeting strategies for hematologic malignancies. Theme 2: Develop novel therapeutic approaches for early-phase clinical testing. Theme 3: Advance translational research in hematopoietic cell transplantation (HCT) and adoptive cellular immunotherapy (ACIT). The HM Program improves public health both through its refinement of currently available treatment options for hematological malignancies and its advancement of novel therapies to the clinic, via an intensive Phase I/II investigational drug program. We are exploring multiple avenues of treatment ? chemotherapy, immunotherapy, gene therapy, targeted therapy, chimeric antigen receptor T cell therapy and HCT ? to improve patient cure rates and treatment tolerability throughout the disease course. Membership: 37 Program Members representing 8 basic and clinical departments Publications: 319 total. 29.2% intra-programmatic; 35.1% inter-programmatic; 45.5% inter-institutional Funding: $6,409,859 peer-reviewed; $3,670,074 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059209
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Wu, Chenkai; Ashing, Kimlin Tam; Jones, Veronica C et al. (2018) The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. J Behav Med 41:52-61
Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Paz, Helicia; Joo, Eun Ji; Chou, Chih-Hsing et al. (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17:235-245
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828

Showing the most recent 10 out of 1396 publications